Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezatiostat in Lenalidomide-Refractory del(5q) MDS
NCT01422486Phase 2Terminated
- Sponsor
- Telik, Inc.
- Start
- Oct 2011
- Primary completion
- Feb 2013
- Modality
- Peptides, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ezatiostat in myelodysplastic syndrome (MDS), sponsored by Telik, Inc. Primary endpoint: Hematologic Improvement-Erythroid rate at 32 weeks. Started Oct 2011; status: terminated.
02
Drugs
ezatiostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01422486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422486.